Method for discriminating between benign and malignant prostate tumors
US8213005B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Dec 31, 2009 |
| Grant date | Jul 3, 2012 |
| Priority date | — |
| Expiry date | Jan 23, 2031 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57434
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The method for discriminating between benign and malignant prostate tumors relates to analyzing samples of blood, urine and tissue by fluorescence spectroscopy in order to detect the presence of naturally occurring molecules in the fluids and tissue that serve as biomarkers indicative of cancer in the human body. The analysis can be carried out based on fluorescence emission spectra, fluorescence excitation spectra and synchronous (emission and excitation) spectra of bio-samples. The detection, diagnosis, and follow-up and also discrimination between malignant and benign prostate tumors may be made by comparison of ratios of fluorescence emissions and/or excitation intensities of tryptophan, tyrosine, elastin, collagen, bile pigments, NADH, flavins and various species of porphyrins.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.